Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- 400 Kobayashi Kako Staffers Move to Trust Pharmatech
April 4, 2022
- Ukraine War Disrupts Ryzodeg Supplies to Japan: Novo
April 4, 2022
- Sumitomo Dainippon Renamed “Sumitomo Pharma”
April 4, 2022
- COVID-19 as Catalyst for Introducing Decentralized Clinical Trials in Japan; Some Results Due Out by Year-End
April 1, 2022
- Akebia/Otsuka’s HIF-PH Inhibitor Vadadustat Nixed in US
April 1, 2022
- Asahi Kasei Grabs Japan Rights to VectivBio’s GLP-2 Analog Peptide
April 1, 2022
- Kobayashi Kako Manufacturing Unit Now Under Sawai; 170 Staffers Remain for Compensation, Drug Handover
April 1, 2022
- Daiichi Sankyo to Offload Cravit Business in China to Local Firm
April 1, 2022
- Sumitomo Dainippon Kicks Off PI/II Study for AML Drug
April 1, 2022
- Ono Bags Global Rights to Numab’s Multispecific I/O Antibody
April 1, 2022
- Healios’ Cell Processing Center in Kobe to Begin Full Operations in Mid-2022
March 31, 2022
- Sandoz to Exclusively Sell Nichi-Iko’s Avastin Biosimilar in Japan
March 31, 2022
- Sumitomo Dainippon to Set Up Holding Firm in China
March 31, 2022
- Pfizer Files Precedex for New Pediatric Indication as “Specific Use Drug”
March 31, 2022
- Ono Collaborates with French Startup in AI-Based Drug Discovery
March 31, 2022
- Kyorin Ties Up with US Biotech for Drug Discovery Research Using Protein Engineering
March 31, 2022
- Taiho’s Biliary Cancer Med Gets US FDA’s Priority Review
March 31, 2022
- Ube, iPSC Startup to Develop IPF Drug, Eyes Clinical Trial in FY2023
March 30, 2022
- MSD Says to Ensure HPV Vaccine Supply in Japan, 4 Million-Plus Syringes for FY2022
March 30, 2022
- JCR to Focus on Partnerships as Core of Growth Strategy: Vice President
March 30, 2022
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…